Kuan-Chieh Tu
Overview
Explore the profile of Kuan-Chieh Tu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
6
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tu K, Chang W, Lin H, Lin P, Wu Y, Lin C, et al.
Eur J Med Res
. 2025 Mar;
30(1):176.
PMID: 40089775
Objective: Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors are a standard therapy for patients who respond poorly to or cannot tolerate statins. However, identifying responders to PCSK9 inhibitors remains unclear....
2.
Yeh T, Tu K, Wang H, Chen J
Int J Mol Sci
. 2024 Feb;
25(3).
PMID: 38339031
This article provides a thorough overview of the biomarkers, pathophysiology, and molecular pathways involved in the transition from acute kidney injury (AKI) and acute kidney disease (AKD) to chronic kidney...
3.
Hsiao C, Pan H, Wu V, Su C, Yeh T, Chuang M, et al.
Front Med (Lausanne)
. 2023 Oct;
10:1252990.
PMID: 37795409
Background: COVID-19 and influenza can both lead to acute kidney injury (AKI) as a common complication. However, no meta-analysis has been conducted to directly compare the incidence of AKI between...
4.
Tu K, Yu R, Lin Y, Chien C, Lu C
Eur J Med Res
. 2023 Sep;
28(1):337.
PMID: 37697336
Background: Intertwined association between infectious gastroenteritis (IGE) and inflammatory bowel disease (IBD) has not been investigated clearly. We aimed to examine the bidirectional association between IGE and IBD. Methods: A...
5.
Yeh T, Tu K, Hung K, Chuang M, Chen J
PLoS One
. 2022 Dec;
17(12):e0279680.
PMID: 36584227
Background: Beta-blockers has been reported to improve all-cause mortality and cardiovascular mortality in patients receiving dialysis, but type of beta-blockers (i.e., high vs. low dialyzable) on patient outcomes remains unknown....